Group One Trading’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-300
| Closed | -$1K | – | 5671 |
|
|
2017
Q4 | $1K | Sell |
300
-1,200
| -80% | -$4.91K | ﹤0.01% | 4775 |
|
|
2017
Q3 | $6K | Hold |
1,500
| – | – | ﹤0.01% | 4459 |
|
|
2017
Q2 | $6K | Buy |
+1,500
| New | +$5.95K | ﹤0.01% | 4398 |
|
|
2017
Q1 | – | Sell |
-5,000
| Closed | -$22K | – | 5287 |
|
|
2016
Q4 | $22K | Buy |
5,000
+4,167
| +500% | +$26.9K | ﹤0.01% | 3674 |
|
|
2016
Q3 | $8K | Buy |
833
+133
| +19% | +$943 | ﹤0.01% | 4125 |
|
|
2016
Q2 | $4K | Sell |
700
-3,633
| -84% | -$24.7K | ﹤0.01% | 4345 |
|
|
2016
Q1 | $33K | Buy |
4,333
+1,633
| +60% | +$12.6K | ﹤0.01% | 3489 |
|
|
2015
Q4 | $36K | Sell |
2,700
-5,483
| -67% | -$94.4K | ﹤0.01% | 3613 |
|
|
2015
Q3 | $135K | Sell |
8,183
-11,184
| -58% | -$229K | ﹤0.01% | 2817 |
|
|
2015
Q2 | $435K | Buy |
19,367
+16,817
| +659% | +$266K | 0.01% | 1901 |
|
|
2015
Q1 | $25K | Sell |
2,550
-8,800
| -78% | -$86.3K | ﹤0.01% | 3779 |
|
|
2014
Q4 | $129K | Buy |
11,350
+3,200
| +39% | +$34.7K | ﹤0.01% | 2654 |
|
|
2014
Q3 | $94K | Sell |
8,150
-9,833
| -55% | -$150K | ﹤0.01% | 3058 |
|
|
2014
Q2 | $350K | Buy |
17,983
+7,750
| +76% | +$137K | 0.01% | 1943 |
|
|
2014
Q1 | $184K | Sell |
10,233
-21,717
| -68% | -$357K | ﹤0.01% | 2514 |
|
|
2013
Q4 | $337K | Sell |
31,950
-783
| -2% | -$8.75K | 0.01% | 1974 |
|
|
2013
Q3 | $405K | Sell |
32,733
-117
| -0.4% | -$1.23K | 0.01% | 1796 |
|
|
2013
Q2 | $307K | Buy |
+32,850
| New | +$422K | 0.01% | 1774 |
|
Group One Trading's CASC Position: Q1 2018 in Review
Group One Trading sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 593 shares — an estimated $2K sold.
Group One Trading first reported a position in CASC in Q2 2013 and held it in 16 quarters. The position peaked at $439K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Group One Trading reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Group One Trading sold 593 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2K.
- Group One Trading first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
- Group One Trading's Cascadian Therapeutics, Inc. position peaked at $439K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Group One Trading's 13F filing for Q1 2018, filed 11 May 2018.